The Mumbai-based Regenerative Medical Services (RMS) Regrow, a cell therapy service provider focusing on orthopaedic and wound healing segments, is planning to launch a bio derived atelocollagen suitable for reconstruction of human tissue in wound management, in collaboration with its strategy partner, the Korea-based Sewon Cellontech.
Theraform, a sterile, pliable, porous surgical wound dressing made of highly purified type I atelocollagen derived from porcine skin is intended for the management of wound care including partial and full-thickness wounds, various ulcers, surgical wounds, trauma wounds and draining wounds. The company is finalising the cost of the product and dealeRs.for the marketing network and is expected to launch the product in a couple of months in India, informs Satyen Sanghvi, chief scientific officer, RMS Regrow.
“At present, doctoRs.are using non-absorbable collagens for wound dressing and later would resort to skin grafting in treating major wound healing. Theraform is a biocollagen, which is an absorbable atelocollagen implant for soft tissue regeneration agent. The product would be manufactured by our partner Sewon Cellontech and we are expecting to launch in within two months' time in India,” said Sanghvi.
He said that the Indian wound care market is around Rs.650 crore or more, and there exists a lack of awareness among the physicians and public about the wound management therapy. Though the cost of the product has not been finalised the treatment would be available at a cost of Rs.5000 to 10000, depending on the size of the wound, he added. The company will spread awareness at the hospitals throughout the country.
The product could address the partial and full-thickness wounds and also the oral wounds by augmentation in mucosal defects and around implants placed in extraction sockets, alveolar ridge reconstruction, and guided tissue regeneration in periodontal defects and intrabony defects.
The company is conducting studies to integrate usage of its existing product Ossron, an autologous bone regeneration therapy, with atelocollagen as part of expanding its operations to the area of regenplasty.
Further, the company also has plans to optimise the use of Ossron, launched in India in collaboration with Sewon Cellontech, by extending the usage to treat osteoporotic fractures mainly affecting the women in post menopausal age. RMS Regrow is also conducting studies on another existing product, Chondron, an autologus cartilage regenaration therapy to expand its use in other therapeutic areas.
The company, at present has six centres for its cell therapy services, in New Delhi, Mumbai, Bangalore, Pune, Hyderabad and Ahmedabad and is planning to set up another centre in Chennai soon. The BabyCell division, which is for cord blood banking has 12 to 14 centres across the nation, mostly on the tier II cities and cateRs.50 per cent of the company's business, said Sanghvi.